已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Continuous intravenous tirofiban can improve the 90-day functional outcome and decrease 90-day mortality without increasing bleeding risk in acute ischemic stroke patients treated by endovascular therapy: A meta-analysis

替罗非班 医学 改良兰金量表 优势比 随机对照试验 内科学 冲程(发动机) 脑出血 麻醉 外科 蛛网膜下腔出血 缺血 缺血性中风 心肌梗塞 机械工程 经皮冠状动脉介入治疗 工程类
作者
Aiwu Zhang,Nihong Wu,Xintong Liu,Tao Jiang
出处
期刊:Journal of Clinical Neuroscience [Elsevier BV]
卷期号:99: 109-116 被引量:7
标识
DOI:10.1016/j.jocn.2022.03.008
摘要

Background The role of continuous intravenous administration of tirofiban in endovascular therapy is still unclear. This meta-analysis aims to evaluate the 90-day functional prognosis in acute ischemic stroke patients (AIS) treated by endovascular treatment and intravenous administration of tirofiban. Methods We searched PubMed, Embase, and CENTRAL databases with the subject terms “tirofiban”, “brain ischemia”, and some related free words. Inclusion criteria were: (1) cohort study or randomized control trials; (2) AIS patients who received endovascular therapy; (3) the intervention or exposure was intravenous tirofiban monotherapy or combined with intra-arterial tirofiban; (4) containing data on modified Rankin Scale at 90 days and including at least one of the following indicators: mortality, symptomatic intracranial hemorrhage (sICH), intracranial hemorrhage (ICH), and recanalization. A summary odds ratio was calculated. Results Twelve eligible studies, consisting of 3268 AIS participants, were identified. There was a significant trend of favorable outcomes (measured by mRS at three months) in the tirofiban group (ORs = 1.36; 95% CI = 1.09–1.70). In addition, compared with the non-tirofiban group, intravenous tirofiban was significantly associated with decreased risk of 90-day mortality (ORs = 0.73; 95% CI:0.59–0.89) and increased recanalization rate (ORs = 1.50; 95% CI:1.08–2.09) but no significant difference in rates of sICH (ORs = 0.93; 95% CI = 0.70–1.24) or ICH (ORs = 0.84; 95% CI = 0.62–1.15). Conclusions Intravenous tirofiban appears to be safe and effective when used following intra-arterial tirofiban or as monotherapy in AIS patients treated by endovascular therapy, which can improve the 90-day functional outcome, decrease the 90-day mortality and increase the possibility of early recanalization without increasing rates of sICH and ICH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
雨濛完成签到 ,获得积分10
4秒前
星辰大海应助忐忑的冰蓝采纳,获得10
5秒前
隐形曼青应助陈朋采纳,获得10
6秒前
Li应助大胆的青荷采纳,获得10
7秒前
传奇3应助LantyLiao采纳,获得10
8秒前
8秒前
斯文的慕蕊完成签到 ,获得积分10
10秒前
10秒前
已有琦琦勿扰完成签到 ,获得积分10
13秒前
小蘑菇应助zhang采纳,获得10
14秒前
lhn发布了新的文献求助10
14秒前
15秒前
ff完成签到,获得积分10
16秒前
浮游应助小粉采纳,获得10
19秒前
19秒前
19秒前
开朗的钻石完成签到,获得积分10
20秒前
林好事完成签到 ,获得积分10
20秒前
20秒前
资山雁完成签到 ,获得积分10
21秒前
FashionBoy应助等待的香魔采纳,获得10
22秒前
5annnn发布了新的文献求助10
22秒前
一盘唐僧肉完成签到,获得积分20
23秒前
小孙失策了完成签到 ,获得积分10
23秒前
24秒前
24秒前
25秒前
25秒前
25秒前
26秒前
26秒前
29秒前
ccm发布了新的文献求助10
29秒前
小树苗发布了新的文献求助30
30秒前
gkads发布了新的文献求助10
30秒前
辰昜发布了新的文献求助10
30秒前
30秒前
30秒前
夜行完成签到 ,获得积分10
30秒前
XIEBUROU发布了新的文献求助10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
A Half Century of the Sonogashira Reaction 1000
Artificial Intelligence driven Materials Design 600
Investigation the picking techniques for developing and improving the mechanical harvesting of citrus 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 500
A Manual for the Identification of Plant Seeds and Fruits : Second revised edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5185289
求助须知:如何正确求助?哪些是违规求助? 4370765
关于积分的说明 13611130
捐赠科研通 4222988
什么是DOI,文献DOI怎么找? 2316110
邀请新用户注册赠送积分活动 1314704
关于科研通互助平台的介绍 1263686